Form D · Pharmaceuticals

HEMOBIOTECH, INC.

Dallas, TX · CIK 0001301348

Offering snapshot reported Jan 25, 2010 · SEC filing

Reported sold
Yet to sell
Offering amount: $3.5M
Investors reported
0
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 25, 2010InitialYet to sellNo comparison0SEC filing
Nov 4, 2009Initial$160,000No comparison5SEC filing
Jan 15, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Not reported
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$350K (estimated)
Finders' fees
$0
Form D file number
021-68647

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Meyers Associates, L.P.34171Bruce Meyers · CRD 1045447

Source: Form D, filed Jan 25, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Baron Director
Arthur P. Bollon Director, Executive
Robert Comer Director
Robert Dragoo Director
Robert Dragoo, Jr. Director
Mario Feola Executive
Bernhard Mittemeyer Director
Bernard Mittemeyer Director
Ghassan Nino Director
Mark Rosenblum Executive
Jan Simoni Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
5001 Spring Valley Road Suite 1040 West
Dallas, TX, 75244